Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2007-5-10
pubmed:abstractText
The structures of both the native holo-HCV NS3/4A protease domain and the protease domain with a serine 139 to alanine (S139A) mutation were solved to high resolution. Subsequently, structures were determined for a series of ketoamide inhibitors in complex with the protease. The changes in the inhibitor potency were correlated with changes in the buried surface area upon binding the inhibitor to the active site. The largest contribution to the binding energy arises from the hydrophobic interactions of the P1 and P2 groups as they bind to the S1 and S2 pockets [the numbering of the subsites is as defined in Berger, A.; Schechter, I. Philos. Trans. R. Soc. London, Ser. B 1970, 257, 249-264]. This correlation of the changes in potency with increased buried surface area contributed directly to the design of a potent tripeptide inhibitor of the HCV NS3/4A protease that is currently in clinical trials.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0022-2623
pubmed:author
pubmed-author:ArasappanAshokA, pubmed-author:BennettFrankF, pubmed-author:BeyerBrian MBM, pubmed-author:BogenStephane LSL, pubmed-author:BruceMalcolmM, pubmed-author:ChenKevinK, pubmed-author:FischmannThierryT, pubmed-author:GirijavallabhanViyyoorV, pubmed-author:GuoZhuyanZ, pubmed-author:HandD PDP, pubmed-author:IngramRichardR, pubmed-author:JaoEdwinE, pubmed-author:LiuYi-TsungYT, pubmed-author:LoveyRaymond GRG, pubmed-author:MadisonVincentV, pubmed-author:MyersJosephJJr, pubmed-author:NjorogeF GeorgeFG, pubmed-author:PichardoJohnJ, pubmed-author:ProngayAndrew JAJ, pubmed-author:ProsiseWinifred WWW, pubmed-author:RamanathanLataL, pubmed-author:SaksenaAnil KAK, pubmed-author:SeniorMaryM, pubmed-author:StricklandCoreyC, pubmed-author:TaremiS ShaneSS, pubmed-author:VenkatramanSrikanthS, pubmed-author:WeberPatricia CPC, pubmed-author:YangRong-ShengRS, pubmed-author:YaoNanhuaN, pubmed-author:Yarosh-TomaineTaisaT, pubmed-author:ZhangRuminR
pubmed:issnType
Print
pubmed:day
17
pubmed:volume
50
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2310-8
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization.
pubmed:affiliation
Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, USA. andrew.prongay@spcorp.com
pubmed:publicationType
Journal Article